Author: Latika Gupta; Durga Misra; Vishwesh Agarwal; Suma Balan; Vikas Agarwal
Title: Management of rheumatic diseases in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India Document date: 2020_4_7
ID: 2kkw9nwa_43
Snippet: For patients in remission and due for IS infusions, 29.8% would defer these infusions while 20.8% would not, and another 39.3% and 20.3% would decide based on severity of the primary disease or the drug being used, respectively. 61% were avoiding Ibuprofen, and 37.10% advised vaccination against other viruses more often during the pandemic. 48.4% rheumatologists had deferred the routine workup for co-morbidities and one-third would consider avoid.....
Document: For patients in remission and due for IS infusions, 29.8% would defer these infusions while 20.8% would not, and another 39.3% and 20.3% would decide based on severity of the primary disease or the drug being used, respectively. 61% were avoiding Ibuprofen, and 37.10% advised vaccination against other viruses more often during the pandemic. 48.4% rheumatologists had deferred the routine workup for co-morbidities and one-third would consider avoiding the use of ACEi/ARBs in RDs, while another one-third were unsure regarding this. Almost three-fourth (70.5%) respondents felt that COVID-19 could cause macrophage activation syndrome (MAS) and Tocilizumab was the preferred drug for treatment (27.6%).
Search related documents:
Co phrase search for related documents- co morbidity and virus vaccination: 1, 2
- drug primary disease and primary disease: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date